Specialized Research

Dalargin

Also known as: Dalargina, Dalar

Molecular Identifiers

Molecular Formula

C35H51N9O8

PubChem CID

6917894

Molecular Weight

726.81 Da

Overview

Synthetic hexapeptide analog of leu-enkephalin, with a molecular weight of approximately 726.81 Da. Developed in the Soviet Union as a gastroprotective agent, it primarily acts on delta-opioid receptors. Widely used in Russian medicine for the treatment of gastrointestinal ulcers and promotion of tissue healing.

Extended notation: Tyr-D-Ala-Gly-Phe-Leu-Arg

Contains D-amino acids

Half-life

~15-30 minutes

Administration Route

Subcutaneous or intramuscular

Category

Specialized Research

Mechanism of Action

  • Selective delta-opioid receptor (DOR) agonism
  • Gastroprotection via reduction of gastric acid secretion
  • Anti-ulcer effect with gastrointestinal mucosal protection
  • Promotion of healing and tissue regeneration
  • Modulation of microcirculation in the gastric mucosa
  • Cytoprotective effect on mucosal cells

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 1-2 mg per injection (subcutaneous or intramuscular)
Frequency 1-2 times daily
Timing Morning and/or evening, preferably fasting
Duration 10-20 days

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Drowsiness
  • Dizziness
  • Mild nausea
  • Bradycardia (high doses)

Presentations & Preparation

Vials of Dalargin found in the research market:

5 mg

Reconstitution

  • Diluent: Bacteriostatic water or sterile saline solution
  • Volume: 1-2 ml per vial
  • Inject the diluent slowly against the vial wall
  • Gently swirl until fully dissolved — never shake
  • Solution should be clear and colorless

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 14 days)
  • Protect from direct light
  • Do not freeze after reconstitution
  • Discard if turbidity occurs
Reconstitution Calculator

Related Peptides

Aviptadil

50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol

B7-33

100-500 mcg per injection (subcutaneous) · Once daily

Bronchogen

5-10 mg per day via subcutaneous injection · Once daily

Cardiogen

5-10 mg per day subcutaneously · Once daily

Chonluten

5-10 mg per day subcutaneously · Once daily

Crystagen

5-10 mg per day via subcutaneous injection · Once daily